Swiss drug major Roche (ROG: SIX) yesterday reported positive results from a mid-stage trial on vismodegib at the 7th European Association of Dermato-Oncology (EADO) Congress taking place in Nantes, France.
Vismodegib is being developed under a deal between Roche subsidiary Genentech with USA-based Curis (NasdaqGM: CRIS) for the treatment of advanced basal cell carcinoma (BCC). The Phase II trial (ERIVANCE BCC) involved patients whose lesions could not be operated, or for whom surgery would result in substantial deformity.
Sales of less than $500 million anticipated in this indication
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze